Effectiveness of clinically active antineoplastic drugs in a surgical-adjuvant chemotherapy treatment regimen using the lewis lung (LL) carcinoma
✍ Scribed by Philip C. Merker; Isidore Wodinsky; Margaret L. Cantor; John M. Venditti
- Book ID
- 102867935
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- French
- Weight
- 641 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Surgical‐adjuvant chemotherapy studies were done with BDF~1~ mice bearing Lewis Lung (LL) carcinoma implanted intramuscularly (IM). Ten days (D10) after implantation, the tumor‐bearing leg was surgically amputated, and intraperitoneal (IP) drug treatment was started either 3 or 5 days after surgery using single‐dose therapy or intermittent treatment given every 4 days for three doses or daily treatment for five doses. The percentage increase in life span (%ILS) was used as the primary measure for evaluation. Data for 17 clinically active drugs showed that surgical‐adjuvant, single‐agent chemotherapy was markedly effective (%ILS>100) in prolonging the life span of tumor‐bearing animals given BCNU, MeCCNU, and cytoxan; moderate activity (%ILS, 40–100) was obtained with bleomycin and vincristine, and marginal activity (%ILS, 35–40) was observed with 5‐fluorouracil (5‐FU), hexamethylmelamine (HMM), procarbazine, and dibromodulcitol. Surgical‐adjuvant, two‐drug‐combination chemotherapy treatment with bleomycin plus MeCCNU or cis‐platinum [cis‐PT(II)] plus CCNU were more effective than single‐drug chemotherapy in prolonging the life span of tumor‐bearing animals. When used in a surgical‐adjuvant chemotherapy‐treatment schedule, the solid tumor model was found to be sensitive to certain antineoplastic drugs that are of clinical benefit in the treatment of human lung cancer. Thus, the model is potentially useful in the search for newer single agents and combinations of drugs against cancers.